Designing thrombolytic agents: Focus on safety and efficacy

The American Journal of Cardiology

Volumn 69, Issue 2, 1992, Pages

  Collen, Désiré ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANISTREPLASE; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE;

ACUTE HEART INFARCTION; BLEEDING; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PRIORITY JOURNAL; REVIEW;

CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMAN; MYOCARDIAL INFARCTION; RECOMBINANT PROTEINS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0026511268     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9149(92)91173-2     Document Type: Article

References (51)

1. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM) mortality morbidity and infarct size at 21 days
2. Long term effects of intravenous thrombolysis in acute myocardial infarction final report of the GISSI study
3. Randomized trial of intravenous streptokinase oral aspirin both or neither among 17187 cases of suspected acute myocardial infarction ISIS-2
4. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavian Study of Early Thrombolysis (ASSET)
5. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial
6. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial
7. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin
8. ISIS-3. Reported at a press conference preceding the American College of Cardiology meeting in Atlanta
9. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?
10. Thrombolytic therapy. Correspondence
11. Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
12. On the future of thrombolytic therapy in acute myocardial infarction
13. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction
14. Plasminogen Activator Italian Multicenter Study (PAIMS). Comparison of intravenous recombinant singlechain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction
15. GISSI-2 a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction
16. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction
17. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction
18. Teichman SL: Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
19. Early intravenous heparin improves coronary patency in thrombolysis with recombinant human tissue-type plasminogen activator
20. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction
21. Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarction
22. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction
23. The Thrombolysis in Myocardial Infarction (TIMI) trial phase I findings
24. TAMI-5: a randomized trial of combination thrombolytic therapy and immediate cardiac catheterization (abstr)
25. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German activator urokinase study (GAUS)
26. A double-blind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction
27. Thrombolysis in Myoeardial Infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator
28. Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction
29. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator, prevention by a maintenance infusion
30. Update from the thrombolysis in myoeardial infarction trial
31. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction
32. Recombinant plasminogen activator inhibitor-1 reverses the bleeding tendency associated with combined administration of tissue-type plasminogen activator and aspirin in rabbits
33. Correlation of bleeding with template bleeding times and hemostasis parameters during separate and combined administration of recombinant tissue-type plasminogen activator, aspirin and aprotinin in dogs
34. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator
35. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myoeardial infarction
36. Tissue-type plasminogen activator: mutants, variants and adjunctive treatment
37. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains in a hamster pulmonary embolism model
38. Ramjit DR: Thrombolytic efficacy of i.v. bolus vampire bat salivary plasminogen activator (bPA) in a rabbit model of femoral arterial thrombosis: comparison to tissue-type plasminogen activator (t-PA) (abstr)
39. Serpin-resistant mutants of human tissue-type plasminogen activator
40. Thrombolytic and pharmacokinetic properties of chimeric (tissue-type/urokinase-type) plasminogen activators
41. Pharmacokinetics and thromborytic properties of chimaeric plasminogen activators consisting of the NH2-terminal region of human tissue-type plasminogen activator and the COOH-terminal region of human single chain urokinase-type plasminogen activator
42. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA)
43. Antibody-directed urokinase: a specific fibrinolytic agent
44. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin
45. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model
46. Conjugation of urokinase to an antiplatelet antibody results in a more potent fibrinolytic agent (abstr)
47. Effect of chemical conjugates of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies, on platelet aggregation and on plasma clot lysis in vitro and in vivo
48. Coronary thrombolysis. Editorial overview
49. Prevention of thrombosis and rethrombosis. New approaches
50. Conjunctive antithrombotic and thromborytic therapy for coronary-artery occlusion